Hyaluronan 35 prevents endotoxin-mediated dysregulated skeletal muscle proteostasis during ethanol exposure.
Nicole Welch, Pugazhendhi Kannan, Gangarao Davuluri...
https://pubmed.ncbi.nlm.nih.gov/41494657/Actively Recruiting
Led by The Cleveland Clinic · Updated on 2026-09-24
54
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the effects of sodium hyaluronate 35kDa HA35 compared to a placebo in adults with alcoholic hepatitis. This early phase 1 study aims to understand how HA35 impacts skeletal muscle mass over 90 days when added to the standard of care treatment. Patients must meet specific clinical criteria related to alcohol consumption and liver function to participate. Participants will be randomly assigned to one of two groups one receiving a daily capsule of HA35 alongside standard care, and the other receiving a placebo capsule with standard care, both for 90 days. The study includes two in-person visits at the start and end of the treatment period, with two additional phone visits at days 30 and 60 to monitor compliance and collect questionnaire data. During visits, participants undergo physical exams, clinical lab tests, body composition scans, muscle strength assessments, and provide urine and stool samples. They will also consume a sugar cocktail to measure gut permeability and have a muscle biopsy taken. The study tracks changes in skeletal muscle mass from baseline to day 90, with careful monitoring through questionnaires and compliance checks. Total participation spans approximately three months.
CONDITIONS
HA35 Moderate Alcoholic Hepatitis (AH) Study
S
Srinivasan Dasarathy, MD
A
Annette Bellar
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The Cleveland Clinic
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | HA35 + Standard Care | Placebo + Standard Care | Guideline‑recommended Standard Care |
|---|---|---|---|
| What it is | Capsule of sodium hyaluronate (HA35) plus standard supportive and pharmacologic treatment as defined in the protocol | Capsule of placebo plus the same standard supportive and pharmacologic treatment | Supportive care typically includes abstinence support, nutritional optimization, and corticosteroid therapy for moderate to severe alcoholic hepatitis per guidelines |
| Role in trial | Investigational arm | Control arm receiving placebo | Not part of trial; represents current guideline‑based practice |
| Primary use | Being studied to assess effect on skeletal muscle mass change over 90 days | Placebo comparator to assess HA35 effect | Used to reduce inflammation and support liver recovery in moderate alcoholic hepatitis |
| Administration | Daily oral capsule of HA35 taken for 90 days along with standard care | Daily oral capsule of placebo taken for 90 days along with standard care | Supportive care and corticosteroids administered per clinical guidelines—typically in hospital setting with monitoring |
| Evidence status | Experimental intervention under early investigation; no published human results yet | Control condition in trial; no separate evidence | Corticosteroids have demonstrated short‑term survival benefit in moderate to severe alcoholic hepatitis in multiple studies |
| Important limitations | Early‑phase safety and feasibility trial; small sample size and short duration | Control arm only allows comparison within trial; not general current‑care comparison | Guideline‑based standard care may not reflect trial setting specifics and may perform differently in broader practice |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 90 days
Participants take either sodium hyaluronate 35kDa capsules or placebo daily with breakfast for 90 days while receiving standard care. They complete two in-person visits for exams, tests, and sample collection, and two phone visits to answer questionnaires and report supplement use.
2 in-person visits and 2 phone calls
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Nicole Welch, Pugazhendhi Kannan, Gangarao Davuluri...
https://pubmed.ncbi.nlm.nih.gov/41494657/The Cleveland Clinic
Lead Sponsor